Amneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2026 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.950-1.050 for the period, compared to the consensus earnings per share estimate of 0.950. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion. Amneal Pharmaceuticals also updated its Q1 2026 guidance to 0.270-0.270 EPS.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ AMRX opened at $13.02 on Wednesday. The stock has a market cap of $4.10 billion, a price-to-earnings ratio of 56.61 and a beta of 1.32. The business has a 50 day simple moving average of $13.17 and a 200 day simple moving average of $12.53. Amneal Pharmaceuticals has a 52 week low of $7.02 and a 52 week high of $15.42.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Wednesday, April 22nd. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.11. Amneal Pharmaceuticals had a negative return on equity of 228.24% and a net margin of 2.39%.Amneal Pharmaceuticals has set its FY 2026 guidance at 0.950-1.050 EPS and its Q1 2026 guidance at 0.270-0.270 EPS. On average, analysts predict that Amneal Pharmaceuticals will post 0.9 EPS for the current year.

Analyst Upgrades and Downgrades

AMRX has been the subject of a number of recent analyst reports. Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. UBS Group initiated coverage on Amneal Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $19.00 target price for the company. Finally, Truist Financial upped their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Rubric Capital Management LP raised its stake in shares of Amneal Pharmaceuticals by 5.3% in the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock valued at $123,473,000 after purchasing an additional 624,609 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Amneal Pharmaceuticals by 3.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 5,609,040 shares of the company’s stock valued at $70,681,000 after purchasing an additional 177,906 shares in the last quarter. Morgan Stanley raised its stake in shares of Amneal Pharmaceuticals by 37.5% in the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock valued at $60,708,000 after purchasing an additional 1,315,018 shares in the last quarter. Nantahala Capital Management LLC raised its stake in shares of Amneal Pharmaceuticals by 14.7% in the second quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after purchasing an additional 558,877 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Amneal Pharmaceuticals by 3.4% in the fourth quarter. State Street Corp now owns 4,110,410 shares of the company’s stock valued at $51,791,000 after purchasing an additional 136,662 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.